1Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation. Circulation 1996; 93: 1262-1277.
2Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflam- mation as a risk factor for atrial fibrillation. Circulation 2003; 108: 3006-3010.
3Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997; 96: 3542-3548.
4Lin Y J, Tsao HM, Chang SL, et al. Prognostic implications of the high-sensitivity C-reactive protein in the catheter ablation of atrial fibrillation. Am J Cardio12010; 105: 495-501.
5Barassi A, Pezzilli R, Morselli-Labate AM, et al. Serum amyloid and C-reactive protein independently predict the re- currences of atrial fibrillation after cardioversion in patients with preserved left ventricular function. Can J Cardiol 2012; 28: 537-541.
6Conway DSG, Buggins P, Hughes E, et al. Relation of inter- leukin-6, C-reactive protein, and the prothrombotic state to tmnsesophageal echocardiographic findings in atrial fibrilla- tion. Am J Cardio12004; 93: 1368-1373.
7Li X, Zima AV, Sheikh F, et al. Endothelin-l-induced arrhythmogenic CaR+ signaling is abolished in atrial myocytes of inositol-l,4,5-trisphosphate (IP3)-receptor type 2-deficient mice. Circ Res 2005; 96: 1274-128l.
8Kourliouros A, Savelieva I, Kiotsekoglou A, et aI. Current concepts in the pathogenesis of atrial fibrillation. Am Heart J 2009; 157: 243-252.
9Watts SW, Thakali K, Smark C, et al. Big ET-1 processing into vasoactive peptides in arteries and veins. Vascul Phar- maco12007; 47: 302-312.
10Kwon YS, Chi SY, Shin H J, et al. Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension. J Korean MedSci 2010; 25: 1487-1491.
